Securing Patents for New Crystalline Form and Manufacturing Method Following Substance Patent
Intellectual Property Rights Protected Until 2042
Expanding IP Coverage for CMC Development and Commercial Production

Onconic Therapeutics announced on the 31st that it has received a decision for the registration of a US patent regarding the novel crystalline form and manufacturing method of its next-generation synthetic lethal anti-cancer drug candidate, Nesuparib, and has completed the patent fee payment. Currently, the final registration procedures such as patent number assignment by the United States Patent and Trademark Office (USPTO) are underway.


Onconic Therapeutics Research Center. Onconic Therapeutics

Onconic Therapeutics Research Center. Onconic Therapeutics

View original image

This patent relates to the high-purity and highly stable new crystalline form of Nesuparib and its manufacturing method. The patent is valid until May 2042. In addition to the existing substance patent, set to expire in 2036, the scope of rights has been extended to cover both the crystalline form and the manufacturing process.


The crystalline form of a pharmaceutical compound affects the purity and stability of the active pharmaceutical ingredient, as well as product quality consistency and manufacturing reproducibility. Securing patents covering both the crystalline form and its manufacturing method can serve as an intellectual property foundation for future development, approval, and commercial production of pharmaceutical manufacturing and quality control (CMC).


Nesuparib is a dual-target synthetic lethal anti-cancer drug candidate that inhibits both tankyrase, an enzyme that activates cell proliferation signals in cancer cells, and poly ADP-ribose polymerase (PARP), an enzyme that repairs damaged DNA. Phase 2 clinical trials are currently underway for four indications—pancreatic cancer, ovarian cancer, endometrial cancer, and gastric cancer. In addition, combination clinical studies are being conducted with Merck (MSD) Keytruda (ingredient: Pembrolizumab) and Celltrion's Vegzelma (ingredient: Bevacizumab).


Nesuparib has received a total of three orphan drug designations (ODD) from the United States Food and Drug Administration (FDA) for pancreatic cancer, gastric and gastroesophageal junction cancer, and small cell lung cancer. The company is currently engaged in pre-IND (Investigational New Drug) meetings with the FDA, targeting submission of a US Phase 2 clinical trial IND by the end of this year.

This patent has been filed in more than 30 countries worldwide and registered in South Korea, Japan, Eurasia, Australia, Saudi Arabia, Iran, and Chile, among others.



A representative of Onconic Therapeutics stated, "Through the new drug approval and commercialization process of Jakubo, we have recognized the importance of CMC capabilities and securing intellectual property rights, accumulating related experience and know-how." The representative continued, "By applying this know-how to the development of Nesuparib, we have expanded the scope of patent protection as we prepare to begin Phase 2 clinical trials in the United States." The representative further added, "We will strengthen our commercialization foundation with an eye toward approval and commercial production in the future, and will continue our global clinical development efforts."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing